Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Co-Chief Executive Officer | December 06, 2022 | December 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date December 06, 2022 · Filed December 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,872 |
Ending reported balance
After 2022-12-09 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-12-06 · Exercise / conversion · Acquired 3,167 · Balance 5,127 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs). Row 2 · 2022-12-06 · Sale · Disposed 935 · Balance 4,192 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Row 3 · 2022-12-09 · Sale · Disposed 320 · Balance 3,872 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,517 |
Reported balance
After 2022-12-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-06 · Exercise / conversion · Disposed 3,167 · Balance 10,517 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs). F6: The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 35,147 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 35,147 F4: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 60 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 60 F5: The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5: The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.
F6: The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 91,400 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · derivative · entry 8 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 1,280,110 Underlying: Common Stock · 91,400 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 91,400 | $6.35 | $579,933.00 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · nonDerivative · entry 4 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 6,557,371 F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.43, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 91,400 | $0.10 | $9,304.52 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · nonDerivative · entry 3 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 6,648,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 91,400 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · derivative · entry 7 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 1,371,510 Underlying: Common Stock · 91,400 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 91,400 | $6.26 | $571,707.00 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · nonDerivative · entry 2 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 6,557,371 F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.34, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 23:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 91,400 | $0.10 | $9,304.52 |
DisclosureSEC source: 0001387131-18-004753 · bernick-form4_091218.xml · nonDerivative · entry 1 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BF Investment Enterprises, Ltd. Disclosed balance after: 6,648,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001387131-18-001121 · bernick-form4_031518.xml · derivative · entry 1 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: Underlying shares vest as follows: 56,667 shares on the first anniversary date of the grant, 56,667 shares on the second anniversary date of the grant, and 56,666 shares on the third anniversary date of the grant. Read SEC document |
| November 30, 2017 Filed Feb 13, 2018 02:14 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000564 · bernick-form5_123117.xml · nonDerivative · entry 1 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:34 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-qualified stock option (right to buy) · Derivative | 170,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001387131-17-001461 · bernick-form4_031517.xml · derivative · entry 1 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Underlying shares vest as follows: 56,667 shares on the first anniversary date of the grant, 56,667 shares on the second anniversary date of the grant, and 56,666 shares on the third anniversary date of the grant. Read SEC document |
| December 27, 2016 Filed Feb 14, 2017 22:57 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-000845 · brian_bernick-form5.xml · nonDerivative · entry 1 Bernick Brian · CIK 0001532233 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.